New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
09:11 EDTKBIO, SUPN, NDLS, ITMN, VJET, KSS, VIPS, ENPH, RHHBY, DDD, XONE, PRGO, ARUN, SNY, SSYS, PLUGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
News For KSS;PLUG;XONE;VJET;SSYS;DDD;ITMN;SNY;RHHBY;NDLS;ARUN;ENPH;SUPN;PRGO;VIPS;KBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 14, 2015
08:55 EDTKSSKohl's says three-year plan 'very achievable'
Subscribe for More Information
08:49 EDTKSSKohl's: February SSS 'very weak,' March/April SSS accelerated about 200bps
Subscribe for More Information
08:45 EDTKSSKohl's says 'well on our way' to achieving long-term goals
Subscribe for More Information
07:11 EDTVIPS, KSSOptions expected to be active
Subscribe for More Information
07:03 EDTKSSKohl's reports Q1 EPS 63c, consensus 55c
Subscribe for More Information
07:02 EDTKSSKohl's says sales accelerated in March/April period after weak February
Subscribe for More Information
May 13, 2015
19:12 EDTVIPSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Paragon Offshore (PGN), up 10.3%... Shake Shack (SHAK), up 10%... Vipshop Holdings (VIPS), up 6.7%. ALSO HIGHER: Vascular Biogenics (VBLT), up 12.8% and Oncothyreon (ONTY), up 15.5% after release of ASCO presentation data. DOWN AFTER EARNINGS: Identiv (INVE), down 10.3%... Sphere 3D (ANY), down 11.3%... VOXX International (VOXX), down 8.1%. ALSO LOWER: Puma Biotechnology (PBYI), down 21.8% after Neratinib data published in ASCO abstract... Karyopharm Therapeutics (KPTI), down 1.2% after ASCO presentation data released... Gevo (GEVO), down 11.4% after filing to sell common stock and warrants.
18:12 EDTRHHBYGenentech alectinib shrank tumors in about half of ALK-positive NSCLC patients
Subscribe for More Information
17:04 EDTRHHBYGenentech announces interim results from POPLAR study
Genentech, a member of the Roche Group announced interim results from a global, randomized Phase II study, POPLAR, in people with previously treated non-small cell lung cancer, NSCLC. The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high or any level of PD-L1 expression, as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology. “In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The goal of PD-L1 as a biomarker is to identify people most likely to experience improved overall survival with MPDL3280A alone, and which people may be appropriate candidates for a combination of medicines.”
16:08 EDTVIPSVipshop sees Q2 revenue RMB8.7B-RMB8.9B
Effective January 1, the company changed its reporting currency from United States dollars to Chinese Renminbi.
16:07 EDTVIPSVipshop reports Q1 adjusted EPS 13c, consensus 10c
Reports Q1 revenue $1.39B, consensus $1.29B.
15:05 EDTKSSNotable companies reporting before tomorrow's open
Subscribe for More Information
15:04 EDTVIPSNotable companies reporting after market close
Subscribe for More Information
11:28 EDTVIPSStocks with call strike movement; TWTR JCP
Subscribe for More Information
09:57 EDTVIPSVipshop says allegations on independence of board, audit firm unfounded
Vipshop issued a statement in response to recent allegations made by a few short sellers, stating in part: "The allegations also challenge the independence of the company's board and its audit firm. This allegation is unfounded. As required by U.S. securities laws and the NYSE listing requirements, the board of directors of the company performs annual assessments of director independence, and the independent directors identified in the company's 2014 annual report on Form 20-F were determined to have met the independence requirements set forth in applicable laws and listing rules."
09:56 EDTVIPSEquity options with increasing volume
Subscribe for More Information
09:55 EDTVIPSVipshop says short seller allegations 'unfounded, contain numerous errors'
Subscribe for More Information
08:56 EDTENPHEnphase Energy has a conference call hosted by JPMorgan
Subscribe for More Information
07:31 EDTSNYHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use